RECORDATI : SUPPORTS THE FORESTAMI PROJECT

NEWS RELEASE

RECORDATI SUPPORTS THE FORESTAMI PROJECT

Milan, 14 July 2021 - Recordati confirms its commitment to protecting the environment and the sustainable development of local areas where it operates by signing up, as a main partner, to the Forestami project, which seeks to plant three million trees by 2030 in the Metropolitan City of Milan. The project, which aims to slow global warming, reduce energy consumption, remove fine particulate from the air and improve the well-being of citizens, is an ambitious and tangible initiative with the full support of Recordati.

"Improving human health is the cornerstone of our mission", stated Andrea Recordati, CEO of Recordati S.p.A. "The conviction that the health and well-being of present and future generations and the health of our planet are closely interlinked pushes us each day to take conscious action by working to preserve natural resources and contribute to the fight against climate change by minimising our environmental impact.

In this urban forestation project we see a way to make a tangible contribution to the Milanese community, where we have close ties and have operated for years, an opportunity to increase well- being and improve the quality of life here in terms of both environmental and social aspects".

Recordati has a long history of entrepreneurial passion and a strong reputation. It aims to continue growing and creating value in an ethical, enduring and sustainable way, all while protecting people and the environment and supplying safe, high-quality products for its patients.

Forestami is project based on research by Milan Polytechnic University, carried out thanks to the support of the Fondazione Falck and FS Sistemi Urbani and promoted by the Municipality of Milan, Metropolitan City of Milan, Lombardy Region - ERSAF (the regional body for agriculture and forestry services), Parco Nord Milano, Parco Agricolo Sud Milano and the Fondazione di Comunità Milano Città, Sud Ovest, Sud Est e Adda Martesana Onlus, the Fondazione Comunitaria Nord Milano, the Fondazione Comunitaria del Ticino Olona, the University of Milan and the University of Milan Bicocca.

Recordati (Reuters RECI.MI, Bloomberg REC IM), established in 1926, is an international pharmaceutical group listed on the Italian Stock Exchange (ISIN IT 0003828271), with a total staff of more than 4,300, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations in Europe, Russia and other countries of the CIS, Ukraine, Turkey, North Africa, the United States, Canada, Mexico, some South American countries, Japan and Australia. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under licence, from a number of therapeutic areas, including a specialised business dedicated to rare diseases. Recordati is a partner of choice for new product licences for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2020 was €1,448.9 million, operating income was €469.0 million and net income was €355.0 million.

RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.

Registered office
VIA M. CIVITALI, 1	SHARE CAPITAL € 26,140,644.50 fully paid up
20148 MILAN, ITALY	BUSINESS REGISTER OF MILAN, MONZA, BRIANZA and LODI
TEL. [phone]	00748210150
FAX [phone]	TAX CODE/VAT NO. 00748210150

Company subject to management and coordination by Rossini Luxembourg S.àr.l

Further information:
Recordati website: www.recordati.it
Investor Relations	Media Relations
Federica De Medici	Studio Noris Morano
(39) 02 48787146	(39) 02 76004736, (39) 02 76004745
e-mail: [e-mail]	e-mail: [e-mail]

This document contains forward-looking statements relating to future events and future operating, economic and financial results of the Recordati group. By their nature, forward-looking statements involve risk and uncertainty because they depend on the occurrence of future events and circumstances. Actual results may therefore differ materially from those forecast as a result of a variety of reasons, most of which are beyond the Recordati group's control. The information on the pharmaceutical specialties and other products of the Recordati group contained in this document is intended solely as information on the Recordati group's activities and therefore, as such, it is not intended as medical scientific indication or recommendation, nor as advertising.